**Creating Hope Reauthorization Act, HR 7384**

**A market-based incentive for drug development for kids with life threatening illnesses**

The Creating Hope Act pediatric voucher program is a market-based incentive program to encourage drug development for kids who have rare and life-threatening illnesses, including pediatric cancer.

Under the voucher program, if a company develops a drug for kids with rare and life-threatening illness and receives FDA approval for their drug, then they also receive from the FDA a voucher. The voucher comes with rights to a faster FDA review -- called a priority review -- for any future drug and for any disease. The vouchers may also be sold to and used by another company developing drugs for other diseases besides pediatric diseases.

The voucher program has transformed pediatric cancer drug development. Vouchers now trade for around $100 million, a powerful incentive. Since the establishment of the program, 60 drugs have been FDA approved for rare and life-threatening pediatric illnesses. Before 2012, there were few such drugs approved.

The voucher program provides a material incentive for companies to prioritize pediatric drug development. The program has no increase in drug prices, no cost to tax payers, and provides a full compensation to FDA in the form on an additional user fee.

**Legislative history:**

In 2012, Congress passed the Creating Hope Act, 21 USC 360ff, establishing a pediatric priority review voucher program. Congress reauthorized the program in 2016 and 2020. Congress must now reauthorize the program before its sunset on September 31, 2024.

The Creating Hope Reauthorization Act was introduced by Representatives McCaul, Barragan, Bilirakis, Trahan, Burgess and Eshoo. We anticipate Senator Cassidy will once again sponsor the bill in the Senate.

**For more information, please contact:**

Eric Kim (McCaul) [eric.kim@mail.house.gov](mailto:eric.kim@mail.house.gov)

Nancy Goodman [nancygoodman@kidsvcancer.org](mailto:nancygoodman@kidsvcancer.org)